Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
No element in selection
Contact

1 result

Topics : Diseases and conditions
Date : du 28/11/2015 au 28/11/2019
Active substance : pyrazinamide
Active substance : rifampicine
Language : Français

Topic

Diseases and conditions (1)
Plus ...

Practice Guidelines and Other Guides (1)
Plus ...
- Chronic disease guide (1)

Date

Last five years (1)

Français (1)

Active substance

isoniazide (1)
pyrazinamide (1)
rifampicine (1)

Practice guidelines and other guides - 1 result

Active tuberculosis

Chronic disease guide - Posted on 19/6/2017

Download guide

Add to my selection

Advancing quality in the fields of health and social care services

Follow us :

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

eNq1WFFz2jgQfs+vYJihLx1sbEIgdzYZAqZlJunRANdOXzzCXkDUSK4kE+ivP9mmjdMzDRXRAzNYWn+78n7+dtfOzW4TVbbAOKbErVpGo1oBEtAQk6VbnU2H9U71pnvhrNEWFc06RsO3Ola1EkSIc7ea7htzQIQbn+/vBiARgFW7FxWHztcQiGd2icCR8R7x1T2KU5uKs6U4rGxArGjoVuNEZKsVhwsm4+g+UvaVxygAxzysFHfX/mVx3TFTsBNQEw7sDpFlKSgQJcwgYQyI6CMBS8r2pdCLwLc77ctru6nkAvMH4DRhAYyRWI0Z3eIQwnJPKOKg5GTxGE6AbSMQqZNScHMdbLgSOFqj3QN8G5UH3ZO7fbET9UbdurJadqttNS+vWg0lV6zwqMrJIw9h5hlpWW3LBGLKe5JIIFEPoc4gWAGTP8VUjSkTKNKUJMz7z+mmyQ+Dby+SIcQ8jtDeWPNY9VEhhuQ2MCkK+g6SnmDKpExF8pn9gk+SKDL/MOrZQUQ0RZxqVJ8mRBzRktlE9UH0KRGwO55RNfkTuwMXMfDXg/1OSbn0j5N5hANVhZMalAAXs4fRcYHTqA23iMOM6ROHT5iE9JG/vugUk6wp+jjTzVLQmIWWb193ZG1oKb9TXySjjtQfL2E0BlPKEebnqMyILOi5+iJJWg71g6K62Jn1RjRAERzpjnxF5ZG0/NHMaSO+vpcq3ygFfedNVdnyMQG2n2SXpdA4dJ/yrKbLOsRekvOlyFOn7hu0if8Wmzgr8K7Yx8AXteZASIISGtGlVJGaPVwCAZbWZMPboihBQg4aA+DTgtUAJkieI8Oj8QSQpHeOnsuFW5SGbH3Y63tTfzK79Xv96ehfz433DH3HBG0kOVQtGF7IdRxgUjS4631452d/3aHsL2r9Zq3XRphnJlzG58YhOgTPII7keVy7UQAYz24Hvann1lq3Ndu2G1arbll1uyMv3hrG23zt+ueaNCvcPH3v3Xtu4F/JTvnyDMU9YXBptjvXaprCygV9JUTM/zLNFeJ1nibYWLCTa+/NE8V00Oz/VPsd3U4j1BlWv1LvRPqVULCEhmdT8TXpKNuMJ83SN+Rq6YLzqSBvMTSFPs97x9PfJ9Xa9FKPfO7cd7j/MF+WFxGWwBl5yNsYbc3GyHv9/uVp6NMW9viZ3Otzkw1omcrqmhSS+W+KlXLHJBNLhkyqwz+LBT7y4fEoMR0z/+jZvXDM9INn9+I/1+cFTw==

Am77ESSwMfYS0erM